Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 153

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1A
Chunk 153
---

offer and sale of all of the units in our Public Offering were registered under the Securities Act pursuant to a registration statement
on Form S-1, as amended (File No. 333-249452), which was declared effective by the SEC on August 10, 2021 (“Registration Statement”).
ThinkEquity, a division of Fordham Financial Management, Inc. acted as the sole book-running manager for the Public Offering. In connection
with the Public Offering, the Company’s common stock and warrants were registered under Section 12(b) of the Exchange Act and began
trading on The Nasdaq Capital Market, LLC under the symbols “PETV” and “PETVW,” respectively.

27

We
received aggregate gross proceeds from our Public Offering of $11,253,850 (inclusive of the underwriter’s exercise of its overallotment
option to purchase warrants). After deducing underwriting discounts and commissions and other offering expenses, we received net proceeds
of approximately $9,781,000 from the Public Offering.

ITEM
6. RESERVED

Not
applicable.

ITEM
7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

The
following discussion of our financial condition and results of operations should be read in conjunction with our financial statements
and related notes that appear elsewhere in this prospectus. In addition to historical consolidated financial information, the following
discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially
from those discussed in the forward-looking statements. Factors that could cause or contribute to those differences include those discussed
below and elsewhere in this prospectus, particularly in “RISK FACTORS.” We caution the reader not to place undue reliance
on these forward-looking statements, which reflect management’s analysis only as of the date of this prospectus.

We
are a smaller reporting company and have not generated any material revenues to date and have incurred substantial losses in connection
with our limited operations. We need substantial capital to pursue our current plans to bring our first products to market. The first
of such products is a proprietary gel-like protein-based biomedical material for injection into the afflicted body parts of animals suffering
from osteoarthritis or other impairments to be marketed under the trade name Spryng®, formerly known as Spryng®. It will provide
veterinarians an innovative treatment for dogs and horses suffering from osteoarthritis.

The
independent auditor’s report accompanying our